What does change in accrued liabilities mean?

Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.

MapLight Therapeutics, Inc. MPLT Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Acadia PharmaceuticalsACAD

$23.56M+20,408%

MeiraGTx Holdings plcMGTX

-$9.9M-176%

Catalyst PharmaceuticalCPRX

-$9.21M-261%

Rapport Therapeutics, Inc.RAPP

-$3.49M-1,155%

Praxis Precision Medicines, Inc.PRAX

-$17.39M-110%

Maze Therapeutics, Inc. Common StockMAZE

-$4.07M-283%

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B—

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's change in accrued liabilities?: MapLight Therapeutics, Inc. (MPLT) reported change in accrued liabilities of -$1.88M in Q1 2026.
What does change in accrued liabilities mean?: Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.